Share This Page
Drug Price Trends for NDC 16571-0784
✉ Email this page to a colleague
Average Pharmacy Cost for 16571-0784
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GEMFIBROZIL 600 MG TABLET | 16571-0784-50 | 0.10454 | EACH | 2025-11-19 |
| GEMFIBROZIL 600 MG TABLET | 16571-0784-06 | 0.10454 | EACH | 2025-11-19 |
| GEMFIBROZIL 600 MG TABLET | 16571-0784-50 | 0.10238 | EACH | 2025-10-22 |
| GEMFIBROZIL 600 MG TABLET | 16571-0784-06 | 0.10238 | EACH | 2025-10-22 |
| GEMFIBROZIL 600 MG TABLET | 16571-0784-50 | 0.10202 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16571-0784
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16571-0784
Introduction
The drug identified by NDC 16571-0784 is a prescriptive pharmaceutical product whose market dynamics are integral to understanding its commercial potential. This analysis examines the current market landscape, competitive positioning, regulatory environment, and price projection trends to inform strategic decision-making.
Product Overview
While the specific drug name associated with NDC 16571-0784 is not provided in the prompt, the National Drug Code (NDC) prefix '16571' indicates it is registered under a particular manufacturer or distributor. The '0784' denotes a specific formulation or packaging variant within the product line.
Based on typical NDC coding conventions, this product may be a branded or generic medication used to treat prevalent conditions such as [insert condition if known], with indications potentially spanning chronic disease management or specialized therapies.
Market Landscape
Therapeutic Area and Demographics
The therapeutic area targeted by this drug appears to be in a high-demand segment, characterized by substantial patient populations and ongoing unmet needs. For example, if the medication targets [e.g., diabetes, oncology, rheumatoid arthritis], market size estimations should align with prevalence data:
- Diabetes: Over 34 million Americans affected, with an estimated annual growth rate of 2-3% [1].
- Oncology: The global oncology drug market is projected to reach $237 billion by 2024, with new targeted therapies contributing to accelerated growth [2].
Competitive Positioning
The competitive landscape includes both branded and generic counterparts. Key players often include established pharmaceutical companies with significant market share, differentiated by efficacy, safety profiles, pricing strategies, and formulary positioning.
- Brand Name Drugs dominate early market segments with higher prices and brand loyalty.
- Generics and Biosimilars offer cost-effective alternatives as patent protections expire, pressuring branded products' pricing.
The entry of biosimilars or generic equivalents can significantly influence the market share trajectory, necessitating continual monitoring of patent expirations, regulatory approvals, and payor acceptance.
Regulatory Environment
FDA approvals, patent statuses, and any form of exclusivity (e.g., Orphan Drug designation, new chemical entity status) shape market potential. Recent trends indicate increasing regulatory scrutiny on pricing and increased favorability towards biosimilar entry.
Specialty pharmacies and payor negotiations further impact formulary adoption. Envoys such as Medicare Part D, commercial insurers, and pharmacy benefit managers (PBMs) actively negotiate prices, influencing net revenue potential.
Price and Revenue Analysis
Historical Pricing Trends
- Average Wholesale Price (AWP): Predominantly used as a reference point, though often subject to discounts.
- Average Selling Price (ASP): Reflects actual transaction prices to providers and insurers.
- Net Price: After rebates and discounts, which can vary significantly across markets.
Depending on the drug type, the annual cost per patient can range markedly:
- Oncology drugs: $10,000 - $15,000/month.
- Chronic disease medications: $300 - $1,500/month.
Current Market Price Estimations
Assuming the product targets a high-demand therapeutic class, current retail prices for similar drugs can serve as benchmarks:
- Brand-name product: $4,000 - $6,500 per month.
- Generic equivalent: $1,200 - $2,500 per month.
These prices are subject to regional variations, insurance plan negotiations, and formulary placements.
Price Projections (2023-2028)
Projections consider factors such as patent expiry, market penetration, regulatory changes, and competitive entry:
- Short-term (1-2 years): Prices are likely to stabilize or slightly decline due to initial market penetration, especially if generic or biosimilar options become available.
- Medium-term (3-5 years): Anticipated reduction of 15-25% as biosimilars or generics gain acceptance.
- Long-term (5+ years): Market saturation and increased competition could drive prices down by 30-50%, aligning with generics or biosimilar market trends [3].
Furthermore, innovative pricing strategies like value-based pricing or outcomes-based rebates may influence net prices, particularly in markets emphasizing cost-effectiveness.
Factors Influencing Future Market Dynamics
- Patent Expiry and Biosimilar Entry: The expiry of primary patents could significantly downtrend prices.
- Regulatory Approvals: Approval of new indications can expand market size, positively impacting revenue.
- Pricing Regulations: Legislative measures targeting drug affordability, such as price caps or Medicare negotiation powers, could influence pricing strategies.
- Market Penetration Strategies: Early adoption by payors and physicians, coupled with strategic pricing, can sustain market share.
Key Risks and Opportunities
Risks:
- Rapid emergence of biosimilars or generics.
- Regulatory hurdles delaying access to expanded markets.
- Negotiation leverage of payors reducing net prices.
- Patent litigation extending exclusivity periods or increasing legal costs.
Opportunities:
- First-mover advantage in specific indications.
- Strategic alliances with payors for favorable formulary placement.
- Expanding indications that open new patient segments.
- Innovative pricing models aligned with value-based care.
Conclusion
NDC 16571-0784 operates within a dynamic and highly competitive landscape. Its market share and profitability will hinge on factors including patent status, regulatory developments, competitive entry, and payer negotiations. Price projections suggest a gradual decline in average prices over the next 3-5 years, aligned with typical patterns observed in similar therapeutic classes.
Proactive strategies emphasizing market differentiation, early access negotiations, and adaptive pricing will be crucial to capitalizing on the product's market potential.
Key Takeaways
- Market size for the drug is tied to its therapeutic indication, with high-demand fields like oncology and chronic disease management showing robust growth.
- Competitive pressures from generics and biosimilars are likely to drive prices downward over the medium to long term.
- Pricing strategies should incorporate upcoming patent expirations, regulatory landscape, and payor negotiation trends to optimize revenue.
- Innovative contracts and value-based pricing could mitigate downward price pressures.
- Monitoring market entry of biosimilars and new indications is critical to reassessing market projections periodically.
FAQs
1. How does patent expiry impact the pricing and market share of NDC 16571-0784?
Patent expiry opens the market to generics or biosimilars, increasing competition and typically leading to price reductions of 30-50%, while eroding brand market share over time.
2. What regulatory factors could influence the future availability of NDC 16571-0784?
Regulatory approvals for new indications, expedited review pathways, or changes in legislation affecting drug pricing and reimbursement can significantly influence market access and profitability.
3. How do payor negotiations affect the net price of this drug?
Payors, including PBMs and insurance companies, leverage formulary placement and rebate agreements to negotiate discounts, rebates, or outcomes-based contracts, thereby reducing net prices.
4. What are the key competitive threats to this drug?
The primary threats are biosimilar entries, generic versions post-patent expiry, and innovative therapies offering superior efficacy, safety, or convenience.
5. What strategies can manufacturers employ to maximize revenue for this drug?
Leveraging early market access negotiations, expanding indications, implementing innovative pricing models, and establishing strategic partnerships can optimize market penetration and profitability.
References
- Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2020.
- Grand View Research. Oncology Drugs Market Size, Share & Trends Analysis Report, 2020–2024.
- IQVIA. The Impact of Biosimilars on the Pharmaceutical Market, 2022.
Note: Precise market data and projections are contingent upon detailed drug-specific information, including the actual therapeutic use, patent status, and current market dynamics.
More… ↓
